A peptide pulled from the skin of a frog, given before any symptoms appeared, lowered how often mice developed a multiple-sclerosis-like disease and softened it in the ones that got sick. The peptide's day job in the frog is killing bacteria. Its effect here had nothing to do with that.
The molecule is temporin-GHaR6R, a short antimicrobial peptide from the skin of the frog Hylarana guentheri. In a study published July 21 ↗ in Probiotics and Antimicrobial Proteins, researchers gave it to mice as a preventive treatment. The test bed was the standard lab model of multiple sclerosis, called experimental autoimmune encephalomyelitis, or EAE. Mice that got the peptide before the model was induced were less likely to develop the disease. Those that did had milder paralysis and less immune-cell infiltration into the spinal cord. They also lost less myelin, the insulating sheath around nerve fibers whose destruction defines MS.
The cell that did the work
Multiple sclerosis is an immune attack on the brain and spinal cord, and one of its local drivers is microglia, the immune cells that live inside the central nervous system. Microglia can sit in roughly two working states. One, labeled M1, is the inflammatory mode: it pumps out signals that recruit more attack and damage tissue. The other, M2, is the cleanup and repair mode. In EAE the balance tips toward M1.
The peptide tipped it back. It suppressed M1 polarization and pushed microglia toward M2. In a dish, microglia stirred up with a bacterial toxin made less of two inflammatory messengers, TNF-alpha and IL-6, when the peptide was present.
Down to the mitochondria
The more specific finding is where the peptide acted inside the cell. Microglia running in inflammatory mode chop their mitochondria, the cell's power plants, into small fragments. A protein called Drp-1 drives that fragmentation. Two others, MFN1 and MFN2, do the opposite, fusing mitochondria into long connected networks.
The peptide turned Drp-1 down and MFN1 and MFN2 up, both in the spinal cords of the treated mice and in the cultured microglia. It also cut the burst of reactive oxygen the stressed cells throw off and kept their mitochondrial membranes charged. The picture the authors draw is a peptide that shifts microglial metabolism from a fragmented, inflammatory setting to a fused, quieter one, with the calmer immune state following from the metabolic one.
What it is and is not
This is a mouse-and-dish study, and a preventive one: the peptide was given before disease onset, not to treat established illness. EAE is the workhorse model for MS. It helped validate approved therapies like fingolimod and natalizumab, but it has also flattered many compounds that went nowhere in people. Prophylaxis in a mouse is a long way from a pill for someone already diagnosed.
What makes the result worth flagging is the source and the mechanism, not the stage. Antimicrobial peptides are usually studied for what their name says, punching holes in bacterial membranes. This one reaches inside a mammalian immune cell and rewires how it runs its mitochondria. That is a different kind of activity, and it widens the case that this family of molecules has second jobs worth mining. peptidemodel already hosts several temporins characterized for non-antimicrobial roles, including one studied for blood-pressure lowering ↗ and an anticancer variant ↗. GHaR6R is not in the corpus yet, and it is a distinct sequence from those. The shared name is a family label, not a claim that they act alike.